Journal List > Allergy Asthma Respir Dis > v.5(6) > 1059290

Lee, Kim, Jung, Park, and Shin: Photosensitivity caused by dronedarone: A case report

Abstract

Dronedarone is a new antiarrhythmic drug for the treatment of nonpermanent atrial fibrillation. Compared with amiodarone, it is regarded as a safe medication due to its structural differences. In this report, we describe a 56-year-old man who developed photo-sensitivity due to dronedarone. He presented with itchy skin rashes for 1 week. Maculopapular exanthema was localized on the neck, both arms, and both hands, with sparing of the other parts of the body. Dronedarone was prescribed 4 weeks ago when atrial fibrillation occurred. After development of skin rashes, dronedarone was discontinued, and systemic steroid, antihistamine, and topical corticosteroid were administered for 1 week, with improvement in skin rashes. The photopatch test was performed with antiarrhythmic drugs, including dronedarone, amiodarone, and flecainide, 4 weeks after withdrawal of dronedarone. Positive reactions were recorded only to dronedarone at the site exposed to ultraviolet A. He was diagnosed with dronedarone-induced photosensitivity and advised to change the antiarrhythmic medication to others. There have been a few case reports on photosensitivity reactions due to dronedarone, which were diagnosed only by clinical suspicion. However, we suspected photosensitivity and proved it by the photopatch test. Photosensitivity should be considered in patients having skin rashes on the exposed area and taking antiar-rhythmic medication, including dronedarone.

REFERENCES

1. Selvaag E. Clinical drug photosensitivity. A retrospective analysis of reports to the Norwegian Adverse Drug Reactions Committee from the years 1970-1994. Photodermatol Photoimmunol Photomed. 1997; 13:21–3.
crossref
2. Glatz M, Hofbauer GF. Phototoxic and photoallergic cutaneous drug reactions. Chem Immunol Allergy. 2012; 97:167–79.
crossref
3. Monteiro AF, Rato M, Martins C. Drug-induced photosensitivity: photo-allergic and phototoxic reactions. Clin Dermatol. 2016; 34:571–81.
crossref
4. Onoue S, Seto Y, Sato H, Nishida H, Hirota M, Ashikaga T, et al. Chemical photoallergy: photobiochemical mechanisms, classification, and risk assessments. J Dermatol Sci. 2017; 85:4–11.
crossref
5. Vamos M, Hohnloser SH. Amiodarone and dronedarone: an update. Trends Cardiovasc Med. 2016; 26:597–602.
crossref
6. De Ferrari GM, Dusi V. Drug safety evaluation of dronedarone in atrial fibrillation. Expert Opin Drug Saf. 2012; 11:1023–45.
crossref
7. Gecks T, Prochnau D, Franz M, Jung C, Kühnert H, Schliemann S, et al. Toxic epidermal necrolysis during dronedarone treatment: first report of a severe serious adverse event of a new antiarrhythmic drug. Cardiovasc Toxicol. 2015; 15:399–401.
crossref
8. Kuo S, Menon K, Kundu RV. Photosensitivity reaction from dronedarone for atrial fibrillation. Cutis. 2014; 94:E10–1.
9. Ladizinski B, Elpern DJ. Dronaderone-induced phototoxicity. J Drugs Dermatol. 2013; 12:946–7.
10. Kutlubay Z, Sevim A, Engin B, Tüzün Y. Photodermatoses, including phototoxic and photoallergic reactions (internal and external). Clin Dermatol. 2014; 32:73–9.
crossref
11. Wilm A, Berneburg M. Photoallergy. J Dtsch Dermatol Ges. 2015; 13:7–12.
crossref

Fig. 1.
Chemical structure of dronedarone (A) and amiodarone (B).
aard-5-358f1.tif
Fig. 2.
Maculopapular eruptions on the upper body with a photodistributed pattern (A), localized in the forearm and the dorsal area of the hand (B), and the neck with V-neck sign (C) at presentation.
aard-5-358f2.tif
Fig. 3.
Photopatch test results on day 4 showing an erythematous change (1+) with ultraviolet (UVA) (A), and a negative response at the nonirradiated control site (B). 1, dronedarone; 2, amiodarone; 3, flecainide.
aard-5-358f3.tif
TOOLS
Similar articles